ANTIBODY ENGINEERING 97
Place: San Francisco, California, USA,
Holiday Inn, UNION SQUARE
DATE: September 21-24, 1997
KEYNOTE: Richarad A. Lerner, The SCRIPPS RESEACH INSTITUTE
THERAPEUTIC ANTIBODY MEETING 97
DATES: September 21-24, 1997
PLACE: Holiday Inn; Union Square; San Francisco, CA, USA
SPONSOR: Palo Alto Institute of Molecular Medicine
ORGANIZERS:
Dennis R. Burton PhD
The Scripps Research Institute
James W. Larrick MD PhD
Palo Alto Institute of Molecular Medicine
PURPOSE:
This meeting has two principal aims. The first is to serve as a forum for the
presentation and discussion of new findings in the antibody field. The
second is to review and discuss many aspects of the overall direction of
antibody research and application. For the second aim, we have asked leaders
in their areas to include a strong component dedicated to a critical
overview. Also included with each session is an extended panel discussion
during which attendees are encouraged to ask questions and air issues from
the floor. It is hoped that the meeting will be both thought provoking and
influential.
Sunday September 21, 1997 8 pm
Arrival
KEYNOTE ADDRESS: Dr. Richard A. Lerner
The Scripps Research Institute
"Catalytic Antibodies"
THERAPEUTIC ANTIBODY MEETING 97
TENTATIVE PROGRAM--Invited Speakers
Monday September 22, 1997 8:30 am
Sessions:
1. Antibody interaction with antigen
2. The generation of human antibodies
3. Antibodies or modified antibodies as effector molecules
4. Antibodies in the study, prophylaxis and therapy of disease
1. Antibody interaction with antigen
Ian Wilson: How should we view this interaction: lock and key vs induced
fit. What does this mean for antibody "design" e.g. naive library
construction.
Peter Schultz: The concept that affinity maturation results from fixing of
certain conformations.
Peter Colman: Influenza virus neuraminidase: structure, antibodies, and
inhibitors. Important data relating to changes in antibody structure on
antigen binding
Roy Mariuzza: The structural and energetic basis of idiotype-anti-idiotype
recognition. Beautiful work showing that for an Ab-Ag and Ab-anti-Id the Ab
contact residues are similar but the energetic contributions of these
residues to binding are quite different.
Cyrus Chothia: The prediction of antibody combining sites. Canonical
structures. Motifs. What can and can not be done with AB engineering.
Michael Neuberger: Mechanisms of somatic mutation in antibodies. Can we
harness this in vitro in the foreseeable future?
Neil Greenspan: The measurement of antibody affinity. Significance of
affinity in vivo. What are the normal ranges? Cooperativity in antibody
binding.
Jamie Scott : Epitope definition using peptide phage display libraries.
Richard Houghten: Epitope definition using synthetic peptide libraries
Chair of discussion : David Davies
2. The generation of human antibodies
Objective talks with a strong review component.
Peter Hudson: overview, introduction to various methods, comparison, comments
on humanized antibodies, chimeric, CDR grafting, antibodies by cellular
routes, EBV transformation, hybridomas
Andrew Griffiths: from naive/synthetic phage display libraries
Peter Pack (Morphosys): from synthetic phage display libraries
Paul Parren: from immune phage display libraries
Ton Logtenberg: selection on cells
Carl Borrebaeck: library selection methods, SIP, CLAP
Jim Marks: The in vitro improvement of antibody affinity
Carlos Barbas: The in vitro improvement of antibody affinity
Aya Jacobvits: from transgenic mice
Chair of Discussion: Andreas Pluckthun
3. Antibodies or modified antibodies as effector molecules
Sherie Morrison: Natural effector systems. How good is complement at killing
antibody-targeted cells and viruses in vivo in humans. What is the role of Fc
receptors. Which Fc receptors, which cells? Decay accelerating factor.
Richard Junghans: The metabolic fate of administered antibody. The Brambell
receptor, molecular basis of catabolism, all seen in new light now receptor
is identified.
Hermann Waldman: Antibodies with enhanced effector activity.
Ralph Reisfeld : Antibody-cytokine fusions
Ira Pastan: Immunotoxins
Michael Pfreundschuh: Bifunctional antibodies
Tom Smith: Structural studies on the mechanism of antibody-mediated
neutralization of rhinovirus.
Wayne Maracso: Intracellullar antibodies
Peter Senter: ADEPT
Zelig Eshhar: T bodies
Chair of Discussion : Dennis Burton
4. Antibodies in the study, prophylaxis and therapy of disease
Arturo Casedvall: Historical perspective of the use of antibodies in
infectious disease.
Nancy Haigwood: Passive immunotherapy in the SIV model
Dennis Burton: The antibody response to HIV-1
Anthony Williamson : Antibodies and the prion problem.
Marty Rosenberg: RSV prophylaxis; other targets under study at SKB
Speaker : anti-TNF
Paula Jardieu: Anti-IgE receptor
Chair of Discussion : Jim Larrick
